Lineage Cell Therapeutics, Inc. (LCTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Lineage Cell Therapeutics, Inc. (LCTX) is down 28.1% since the beginning of the year. At $1 per share, LCTX is trading 42.6% below its 52-week high of $2. Investors who bought $1,000 worth of LCTX shares 5 years ago would now be looking at an investment worth $419.

Lineage Cell Therapeutics, Inc. (LCTX) has returned -28.14% so far this year and 76.99% over the past 12 months. Over the last ten years, LCTX has returned -6.85% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Mar 6, 1992, LCTX's average daily return is +0.14%, while the average monthly return is +1.97%. At this rate, an investment would double in approximately 3.0 years.

Historically, 42% of months were positive and 58% were negative. The best month was Aug 2008 with a return of +152.9%, while the worst month was Aug 2005 at -38.8%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 11 months.

On a daily basis, LCTX closed higher 41% of trading days. The best single day was Nov 15, 2002 with a return of +95.9%, while the worst single day was Jul 31, 2006 at -35.9%.

Lineage Cell Therapeutics, Inc. has an annualized alpha of 30.51%, beta of 0.89, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since March 09, 1992.

• This stock participated in 147.76% of S&P 500 Index downside but only 99.47% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

LCTX ranks 74 for risk / return — better than 74% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Lineage Cell Therapeutics, Inc. (LCTX) and compare them to S&P 500 Index.

Lineage Cell Therapeutics, Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Lineage Cell Therapeutics, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Lineage Cell Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Lineage Cell Therapeutics, Inc. was 99.31%, occurring on Aug 28, 2006. The portfolio has not yet recovered.

The current Lineage Cell Therapeutics, Inc. drawdown is 93.85%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Lineage Cell Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Lineage Cell Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.